Form 4: Evoke Pharma Acquired: CFO Disposes Shares, Options

Evoke Pharma Inc. has been acquired by QOL Medical, LLC, with Chief Financial Officer Mark Kowieski disposing of his common stock and converting options into cash.

Summary

• Evoke Pharma Inc. was acquired by QOL Medical, LLC and QOL-EOS Merger Sub, Inc. through a tender offer and subsequent merger.
• The tender offer was completed on December 16, 2025, with all outstanding common stock acquired for $11.00 per share in cash.
• Effective December 17, 2025, Merger Sub merged with Evoke Pharma Inc., making Evoke Pharma a wholly-owned subsidiary of QOL Medical, LLC.
• Chief Financial Officer Mark Kowieski disposed of 11,815 shares of common stock on December 16, 2025.
• His outstanding stock options, with exercise prices of $5.27 and $4.45, were accelerated, fully vested, and converted into cash based on the $11.00 offer price, effective December 17, 2025.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of an acquisition, providing a cash exit for shareholders and converting executive stock options into cash at a premium. This is generally a positive outcome for the selling shareholders and option holders.

Positives

• Shareholders received $11.00 per share in cash for their common stock, providing a clear exit and liquidity.
• Stock options held by management, including CFO Mark Kowieski, were accelerated, fully vested, and converted into cash at a premium to their exercise prices.

Negatives

• Evoke Pharma Inc. is no longer an independent publicly traded company.
• Public shareholders no longer have an equity stake or future upside potential in Evoke Pharma.

Risks

• No future risks for the public entity as it has been acquired and delisted.
• For the reporting person, the risk associated with holding Evoke Pharma securities has been eliminated through the cash conversion.

Future Outlook

Evoke Pharma Inc. is now a wholly-owned subsidiary of QOL Medical, LLC, and as such, its future operations and strategic direction will be determined by its new parent company, with no independent public outlook.

Industry Context

The acquisition of Evoke Pharma Inc. by QOL Medical, LLC reflects a common trend in the pharmaceutical and biotechnology sectors where larger entities acquire smaller, specialized companies to expand their product portfolios or gain access to specific technologies. Such mergers and acquisitions often provide liquidity for shareholders of the acquired company and can streamline development efforts under a larger corporate umbrella.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Received $11.00 per share in cash, providing liquidity and a defined return on investment.
• Employees (including management): Stock options were accelerated, vested, and converted to cash, providing financial benefit.
• Customers: Potential for continued product availability under new ownership.

Next Steps

• Internal integration of Evoke Pharma Inc. into QOL Medical, LLC's operations.
• Delisting of Evoke Pharma Inc. common stock from public exchanges (implied by the acquisition).

Key Dates

Keywords

Evoke Pharma, EVOK, QOL Medical, acquisition, merger, tender offer, beneficial ownership, Form 4, Mark Kowieski, CFO, stock options, common stock